The Pathway Before Us

The Pathway Development Consortium will guide the recent decades of AAV gene therapy research into a future of innovative, potentially life-saving therapies. Our goal is to foster collaboration and partnership among patients, industry, regulators, academia, payers and other stakeholders. For this reason, REGENXBIO and Solid Biosciences, joined together to launch the Pathway Development Consortium with the vision to construct an ideal pathway to ensure that all born with serious genetic conditions can find their way to effective AAV gene therapies.

Our first focus is to create a collaborative forum for scientific and policy interchanges. We are working quickly to identify opportunities to create more efficient pathways and solutions that will contribute to the development of and access to innovative AAV gene therapies.